• 10x Genomics posted Q2 revenue of $151 million; $1.6 million came from Takara settlement-related license and royalty revenue.
• Excluding non-recurring settlement revenue in both periods, revenue was $149 million, up 3% on year, driven by consumables strength.
• Consumables revenue rose 7%; Single Cell consumables grew 3% on double-digit reaction-volume gains tied to Flex Apex adoption.
• Spatial consumables increased 16% on higher Xenium utilization; instrument revenue fell 47% on fewer units sold.
• Full-year revenue outlook lifted to $610 million-$630 million; Atera orders exceeded the 40-unit shipment plan, with most shipments expected in Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.